Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02810418
Recruitment Status : Active, not recruiting
First Posted : June 23, 2016
Last Update Posted : April 11, 2019
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Brief Summary:

Background:

LMB-100 is a man-made protein designed to kill cancer cells. LMB-100 targets a cancer marker called mesothelin. Mesothelin is found on the surface of many different tumors, including pancreatic cancer, but is made by a very small number of normal tissues. Other cancers that make mesothelin include mesothelioma, cholangiocarcinoma, thymic carcinoma, ovarian, lung, gastric, endometrial, cervical, and ampullary cancers. After binding to the mesothelin on tumors, LMB-100 can attack and kill cancer cells. Researchers want to see how well it works when given with and without nab-paclitaxel, a drug which treats pancreatic cancer.

Objectives:

Arm A- To find a safe dose of LMB-100 with a fixed standard dose of nab-paclitaxel in people with advanced pancreatic cancer. To see how well the combination of the two drugs reduce tumor size.

Arm B- To find a safe dose of LMB-100 when it is given as a continuous infusion over several days.

Eligibility:

Arm A- Adults age 18 and older with advanced pancreatic cancer that has worsened after anti-cancer therapy.

Arm B- Adults age 18 and older with advanced pancreatic cancer, mesothelioma or other solid tumor that makes mesothelin that has worsened after anti-cancer therapy

Design:

Participants will be screened with medical history and physical exam. They will give blood, urine, and tissue samples. They will have scans and x-rays.

During each 21-day cycle:

  • For Arm A

    • Participants will get LMB-100 by an IV catheter on days 1, 3, and 5. This is a tube inserted in a vein, usually in the arm.
    • Participants will get nab-paclitaxel by IV on days 1 and 8.
  • For Arm B

    • Participants will get LMB-100 by an IV catheter as a continuous infusion beginning on day 1 and continuing for 2-4 days
    • Some participants will also get nab-paclitaxel by IV on days 1 and 8.

All participants will get this combination for up to 2 cycles or until their disease worsens or they have intolerable side effects.

Participants will have blood and urine tests and scans throughout the study.

Participants will have a safety follow-up visit 3-6 weeks after treatment ends. If their disease remains stable or improves, they will be scanned every 6 weeks until their disease gets worse. Even if their disease gets worse, they or their doctor will be called to talk about their cancer status.


Condition or disease Intervention/treatment Phase
Neoplasms Pancreatic Neoplasms Drug: LMB-100 Drug: Nab-Paclitaxel Device: Mesothelin Expression Phase 1 Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in Participants With Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Actual Study Start Date : August 3, 2016
Estimated Primary Completion Date : April 30, 2021
Estimated Study Completion Date : January 31, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: Arm A1 (Phase 1, short infusion)
MTD determination in patients with pancreaticcancer receiving short infusion LMB-100+nabpaclitaxel
Drug: LMB-100

Arms A1 and A2 (short infusion): Administered IV on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles

Arms B1 and B2 (continuous infusion): Administered IV for 24,48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 21 day cycle for a maximum of 2 cycles


Drug: Nab-Paclitaxel
Administered IV on days 1, and 8 of each 21 day cycle for a maximum of 2 cycles

Experimental: Arm A2 (Phase 2, short infusion)
efficacy determination in patients with pancreatic cancer receiving short infusion LMB-100 + nabpaclitaxel
Drug: LMB-100

Arms A1 and A2 (short infusion): Administered IV on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles

Arms B1 and B2 (continuous infusion): Administered IV for 24,48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 21 day cycle for a maximum of 2 cycles


Drug: Nab-Paclitaxel
Administered IV on days 1, and 8 of each 21 day cycle for a maximum of 2 cycles

Experimental: Arm B1 (Continuous infusion single agent leadin)
MTD determination in patients with pancreatic cancer receiving contious infusion LMB-100 as single agent
Drug: LMB-100

Arms A1 and A2 (short infusion): Administered IV on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles

Arms B1 and B2 (continuous infusion): Administered IV for 24,48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 21 day cycle for a maximum of 2 cycles


Device: Mesothelin Expression
Research blood test for Arm B1 eligibility

Experimental: Arm B2 (continous infusion combination therapy)
Up to 6 subjects with pancreatic cancer meeting nab- paclitaxel eligibility criteria, followed by an additional 4 subjects if safety is established.
Drug: LMB-100

Arms A1 and A2 (short infusion): Administered IV on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles

Arms B1 and B2 (continuous infusion): Administered IV for 24,48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 21 day cycle for a maximum of 2 cycles


Drug: Nab-Paclitaxel
Administered IV on days 1, and 8 of each 21 day cycle for a maximum of 2 cycles




Primary Outcome Measures :
  1. Objective response rate in phase 2 subjects of short infusion LMB-100+ nab-paclitaxel [ Time Frame: Every 8 weeks until disease progression ]
    the number of partial responses + complete responses divided by thetotal number of patients in the phase 2 Arm A portion of the study

  2. Maximum tolerated dose of short infusion LMB-100 + nab paclitaxel [ Time Frame: 21 days after LMB-100 is administered (end of cycle 1) ]
    highest dose tolerated without exceeding a pre-set number of adverse events in Phase 1, Arm A

  3. Maximum tolerated dose of continuous infusion LMB-100 [ Time Frame: 21 days after LMB-100 is administered (end of cycle 1) ]
    highest dose tolerated without exceeding a pre-set number ofadverse events in Phase 1, 1 Arm B, single agent lead-in

  4. safety and tolerability of continuous infusion LMB-100 + nab-paclitaxel [ Time Frame: 21 days after LMB-100 is administered (end of cycle 1) ]
    adverse events observed in patients in Phase 1 Arm B


Secondary Outcome Measures :
  1. Safety and tolerability of LMB-100 + nab-paclitaxel [ Time Frame: 30 days after the last dose is admistered ]
    adverse events observed in subjects with pancreatic cancer

  2. progression free survival [ Time Frame: At progression ]
    average time from treatment initiation to disease progression or death

  3. overall survival [ Time Frame: At death ]
    average time from treatment initiation to death

  4. disease control rate at 4 months [ Time Frame: 4 months after treatment initiation ]
    proportion of patients with stable disease, partial response or complete response at 4 months

  5. objective response rate Phase 1 Arm 1 [ Time Frame: every 8 weeks until disease progression ]
    the number of partial responses + complete responses divided by thetotal number of subjects in Phase 1, Arm A

  6. objective response rate Phase 1, Arm B [ Time Frame: Every 8 weeks until disease progression ]
    responses + complete responses divided by the total number ofsubjects in Phase 1, Arm B



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:
  • For participants who will be receiving nab-paclitaxel (all arms except Phase I Arm B Single Agent Lead-in)

    • Histologically confirmed recurrent, advanced or metastatic pancreatic ductal adenocarcinoma as determined by NCI Laboratory of Pathology.
    • No treatment with paclitaxel or nab-paclitaxel within 4 months prior to initiation of study therapy
    • ECOG performance p status (PS) 0-1.
    • Adequate hematological function: neutrophil count of greater than or equal to 1.0 x 10(9) cells/L, platelet count of greater than or equal to 95,000/microliters, hemoglobin greater than or equal to 9 g/dL
    • Measurable disease as per the RECIST Criteria v 1.1
    • For participants who will NOT receive nab-paclitaxel (Arm B1 Single Agent Lead-in only)
    • Histologically confirmed solid tumor malignancy for which no curative therapy exists with at least 25% of tumor cells expressing mesothelin as determined by NCI Laboratory of Pathology. Determination can be made using archival tumor tissue or fresh biopsy. Subjects with epithelioid mesothelioma and pancreatic adenocarcinoma are automatically eligible and are not required to have this test.
    • ECOG performance status (PS) 0-2.
    • Adequate hematological function: neutrophil count of greater than or equal to 1.0 x 10(9) cells/L, platelet count of greater than or equal to 85,000/microliters, hemoglobin greater than or equal to 8.5 g/dL
    • Measurable and/or evaluable disease as per the RECIST Criteria v 1.1
  • For all arms of the protocol

    • Participants must have received at least one prior chemotherapy regimen for their disease.
    • Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of LMB-100 in combination with nab-paclitaxel in persons <18 years of age, children are excluded from this study.
    • Participants must be more than 14 days removed from most recent minor surgical procedure (such as biliary stenting), 28 days from most recent major surgical procedure, 14 days removed from most recent radiation therapy, chemotherapy or experimental drug treatment with published half-life known to be 72 hours or less and 28 days removed from last experimental drug treatment with unpublished or half-life greater than 72 hours.
    • All acute toxic effects of any prior radiotherapy, chemotherapy, experimental drug treatment or surgical procedure must have resolved to Grade less than or equal to 1, except alopecia (any grade) and peripheral neuropathy.
    • Serum albumin greater than or equal to 2.5 mg/dL without intravenous supplementation
    • Adequate liver function: Bilirubin, AST and ALT < 2.5 x ULN. AST and ALT up to 5x ULN is permitted for patients with liver metastases.
    • Adequate renal function: creatinine clearance greater than or equal to 50 mL/min.
    • Must have left ventricular ejection fraction > 50%
    • Must have an ambulatory oxygen saturation of > 88% on room air
    • The effects of LMB-100 alone or in combination with nab-paclitaxel on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry until 3 months the last dose of study therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
    • Ability of participant to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

  • Exclusion criteria for all study arms

    • Known or clinically suspected CNS 2.1.2.1 primary tumors or metastases including leptomeningeal metastases. History or clinical evidence of CNS metastases unless they have been previously treated, are asymptomatic, and have had no requirement for steroids or enzyme-inducing anticonvulsants in the last 14 days.
    • Evidence of significant, uncontrolled concomitant diseases which could affect compliance with the protocol or interpretation of results, including significant pulmonary disease other than that related to the primary cancer, uncontrolled diabetes mellitus, and/or significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, unstable angina, or clinically significant pericardial effusion)
    • Any known diagnoses, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition (other than pancreatic adenocarcinoma) that would contraindicate the use of an investigational drug, interfere with tumor measurement or lead to an expected life expectancy of less than 6 months as judged by the investigator
    • Active or uncontrolled infections.
    • Live attenuated vaccinations within 14 days prior to treatment
    • Dementia or altered mental status that would prohibit informed consent
    • Pregnant women are excluded from this study because the effects of LMB-100 on the developing fetus are unknown and may have the potential to cause teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with LMB-100, breastfeeding should be discontinued if the mother is treated with LMB-100. These potential risks may also apply to other agents used in this study.
    • Known hypersensitivity to any of the components of LMB-100
    • Baseline QTcF interval of > 470 ms, participants with baseline resting bradycardia < 45 beats per minute, or baseline resting tachycardia> 100 beats per minute.
  • Exclusion criteria specific to patients who will be receiving nab-paclitaxel (all arms except Arm B1 Single Agent Lead-in)

    • Participants with contra-indication and/or history of severe hypersensitivity reactions to nab-paclitaxel
    • Participants with baseline peripheral neuropathy greater than grade 2
    • HIV or active HBV or HCV infection due to risk of progression while receiving immunosuppressive chemotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02810418


Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Christine C Alewine, M.D. National Cancer Institute (NCI)

Additional Information:
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT02810418     History of Changes
Other Study ID Numbers: 160128
16-C-0128
First Posted: June 23, 2016    Key Record Dates
Last Update Posted: April 11, 2019
Last Verified: April 9, 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Immunotoxin
Mesothelin
Antibody-based Therapeutics
Advanced Cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Adenocarcinoma
Pancreatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Immunotoxins
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs